KM257 + gemcitabine + cisplatin

KM257 + gemcitabine + cisplatin is an investigational combination therapy for advanced HER2-positive or expressing solid tumors, currently being studied in a first-in-human, phase 1 clinical trial. KM257 is a bispecific antibody targeting HER2 (receptor tyrosine-protein kinase erbB-2) and acts as an antagonist. Gemcitabine is a small molecule antimetabolite chemotherapy agent that inhibits DNA synthesis, while cisplatin is a platinum-based chemotherapy drug causing DNA crosslinking and apoptosis. This combination aims to leverage the targeted anti-HER2 effect of KM257 with the cytotoxic actions of gemcitabine and cisplatin to enhance efficacy against various neoplasms[1][2][3][4].